Andrew T, Antioniades L, Scurrah KJ, Macgregor AJ, Spector TD Risk of wrist fracture in women is heritable and is influenced by genes that are largely independent of those influencing BMD. J Bone Miner Res. 2005 Jan;20(1):67-74. Epub 2004 Oct 25.
Arden NK, Baker J, Hogg C, Baan K, Spector TD The heritability of bone mineral density, ultrasound of the calcaneus and hip axis length: a study of postmenopausal twins. J Bone Miner Res. 1996 Apr;11(4):530-4.
Clayton RN, Raskauskiene D, Reulen RC, Jones PW Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J Clin Endocrinol Metab. 2011 Mar;96(3):632-42. doi: 10.1210/jc.2010-1942. Epub 2010 Dec 30. Review.
Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K Frailty in elderly people. Lancet. 2013 Mar 2;381(9868):752-62. doi: 10.1016/S0140-6736(12)62167-9. Epub 2013 Feb 8. Review. Erratum in: Lancet. 2013 Oct 19;382(9901):1328.
Colao A, Ferone D, Marzullo P, Lombardi G Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004 Feb;25(1):102-52. Review.
DeFronzo RA Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 2004 Jul;88(4):787-835, ix. Review.
Dujic T, Zhou K, Tavendale R, Palmer CN, Pearson ER Effect of Serotonin Transporter 5-HTTLPR Polymorphism on Gastrointestinal Intolerance to Metformin: A GoDARTS Study. Diabetes Care. 2016 Nov;39(11):1896-1901. Epub 2016 Aug 4.
Eisman JA Genetics of osteoporosis. Endocr Rev. 1999 Dec;20(6):788-804. Review.
Finkelstein J, Friedman C, Hripcsak G, Cabrera M Potential utility of precision medicine for older adults with polypharmacy: a case series study. Pharmgenomics Pers Med. 2016 Apr 15;9:31-45. doi: 10.2147/PGPM.S101474. eCollection 2016.
Jamaluddin JL, Huri HZ, Vethakkan SR Clinical and genetic predictors of dipeptidyl peptidase-4 inhibitor treatment response in Type 2 diabetes mellitus. Pharmacogenomics. 2016 Jun;17(8):867-81. doi: 10.2217/pgs-2016-0010. Epub 2016 Jun 1.
Joseph SM, Rich MW Targeting Frailty in Heart Failure. Curr Treat Options Cardiovasc Med. 2017 Apr;19(4):31. doi: 10.1007/s11936-017-0527-5. Review.
Kane AE, Gregson E, Theou O, Rockwood K, Howlett SE The association between frailty, the metabolic syndrome, and mortality over the lifespan. Geroscience. 2017 Apr;39(2):221-229. doi: 10.1007/s11357-017-9967-9. Epub 2017 Mar 9.
Ralston SH Genetic determinants of susceptibility to osteoporosis. Curr Opin Pharmacol. 2003 Jun;3(3):286-90. Review.
Ramaswami R, Bayer R, Galea S Precision Medicine from a Public Health Perspective. Annu Rev Public Health. 2018 Apr 1;39:153-168. doi: 10.1146/annurev-publhealth-040617-014158. Epub 2017 Nov 20. Review.
Richards JB, Zheng HF, Spector TD Genetics of osteoporosis from genome-wide association studies: advances and challenges. Nat Rev Genet. 2012 Jul 18;13(8):576-88. doi: 10.1038/nrg3228. Review.
Rocha-Braz MG, Ferraz-de-Souza B Genetics of osteoporosis: searching for candidate genes for bone fragility. Arch Endocrinol Metab. 2016 Aug;60(4):391-401. doi: 10.1590/2359-3997000000178. Review.
Sonino N, Fava GA Psychiatric disorders associated with Cushing's syndrome. Epidemiology, pathophysiology and treatment. CNS Drugs. 2001;15(5):361-73. Review.
Webb SM, Crespo I, Santos A, Resmini E, Aulinas A, Valassi E MANAGEMENT OF ENDOCRINE DISEASE: Quality of life tools for the management of pituitary disease. Eur J Endocrinol. 2017 Jul;177(1):R13-R26. doi: 10.1530/EJE-17-0041. Epub 2017 Mar 28. Review.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.